Infinitas Capital

Einwert is the first European hybrid appraiser that reimagines real estate valuation through an ESG-compliant value experience. The company has developed a real estate value management platform designed to empower appraisers with digital technology, enhancing market transparency and providing sustainability insights. By replacing manual processes with intelligent parameter determination, Einwert offers accurate, sustainability-driven formal valuations. This innovative approach enables clients, particularly real estate investors, to make smarter and more future-oriented decisions that are essential for their business growth.

Wonder Brands is a Latin American startup specialized in partnering with successful digital brands to boost their growth. The implementation of its strategy is achieved by injecting into associated companies a significant investment to exponentially increase working capital, marketing and equipment, as well as providing added value in the areas of technology, digital marketing, supply chain and administration.

Operator of a clinical-stage biopharmaceutical company intended to develop therapies for Alzheimer's disease. The company developed a drug that is an orally administrated small molecule treatment, that enhances the neurotransmission in the brain and improves both cognition and independent global function, it is phase three trial-ready, enabling medical practitioners to use neurotransmission and improve both cognition and independent global function.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

Opeartor of a digital platform intended to convert real estate assets into cash assets. The company provides partial real estate sales of the property places customers at the center of all our considerations and efforts and relies on tailor-made, individual solutions, enabling customers to keep all decision-making options and buy back the part sold at any time or sell the entire property.

Exporo offers investors an overview of real estate projects in which they can invest easily, transparently and free of charge. The idea begins in 2013 with the realization that real estate project developers are increasingly looking for alternative sources of finance, as banks no longer finance entire projects as usual due to stricter regulation, and that private investors only have a lot of money, with good conditions and easy to invest in real estate. The result of this observation is the firm decision to develop its own online marketplace to offer real estate projects as an investment opportunity and to provide capital directly between private investors and real estate companies. Simon Brunke, Björn Maronde, Tim Bütecke and Julian Oertzen founded the online platform in 2014, they are constantly evolving and they are board members of Exporo AG. The company now employs more than 120 people and is based in Hamburg's HafenCity.

Einwert is the first European hybrid appraiser that reimagines real estate valuation through an ESG-compliant value experience. The company has developed a real estate value management platform designed to empower appraisers with digital technology, enhancing market transparency and providing sustainability insights. By replacing manual processes with intelligent parameter determination, Einwert offers accurate, sustainability-driven formal valuations. This innovative approach enables clients, particularly real estate investors, to make smarter and more future-oriented decisions that are essential for their business growth.

AMZSCALE is an agency specializing in Amazon fulfillment services designed to assist third-party eCommerce businesses. Comprising a team of experienced eCommerce professionals who have successfully built and sold their own Amazon brands, the agency provides a range of services aimed at facilitating business growth. These services include detailed research and sourcing, operational excellence, sales infrastructure development, and brand optimization. By leveraging their practical knowledge, AMZSCALE enables clients to enhance their operational capabilities and scale their businesses effectively in the competitive Amazon marketplace.

FORME Life is a modular smart home gym and home fitness system for fitness and strength workouts. The company combines advanced linked fitness devices with coaching and personal training provided by real people to provide an immersive experience and improve results for both clients and trainers.

Storypod is a company focused on fostering children's love of learning through a screen-free, interactive audio platform designed for young users. The platform utilizes a smart audio system powered by RFID-enabled yarn figurines, read-along audiobooks, and trivia cards, allowing children to engage with classic stories, music, and educational games. By providing stage-based content, Storypod aims to support parents, grandparents, and educators in nurturing smart, healthy, and resilient kids while promoting independent learning in a fun and engaging manner.

Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Customuse is a developer of virtual apparel design software that allows users to create and sell wearable augmented reality outfits for virtual avatars. The platform features an intuitive interface and unique templates, making it easy for users to bring their product ideas to life. By enabling the design of virtual clothing, Customuse facilitates the promotion of brands and enhances audience interaction within popular games and on social media. The software empowers users to quickly market their designs in augmented and virtual reality environments, thereby expanding their reach and engagement.

Bullish Global is a new blockchain-based cryptocurrency exchange designed to combine the performance, user privacy, and compliance offered by central order book technology with the vertically integrated user benefits of decentralized finance (DeFi) market architecture.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London, established in 2018. The company focuses on developing therapies for mental health disorders, utilizing psychedelic compounds and other innovative methods to address conditions such as depression, anxiety, and substance use disorders. ATAI collaborates with various partners and research institutions to advance its clinical-stage drug development pipeline, which includes multiple product candidates like psilocybin therapy, ketamine-based treatments, and other compounds aimed at enhancing mental well-being. The company's commitment to research in psychedelics and neuroscience drives its efforts to ensure the efficacy and safety of its therapies. Recognized for its contributions to mental health treatment, ATAI has secured partnerships and funding to support its initiatives, gaining attention for its advancements in understanding and treating mental health disorders.

nextmarkets GmbH, founded in 2014 and headquartered in Cologne, Germany, specializes in developing a user-friendly web and mobile trading platform aimed at private investors. The platform allows users to intuitively trade a wide range of financial instruments, including equities, foreign exchange, bonds, and commodities. Recognizing the challenges faced by private investors—many of whom struggle in the stock market due to behavioral economic factors—nextmarkets provides educational resources and trading strategies to enhance users' understanding of market dynamics. By equipping investors with the necessary tools and knowledge, nextmarkets aims to promote sustainable and informed trading practices.

Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Sensei Biotherapeutics is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. The company is dedicated to developing precision cancer therapeutics that target tumor-specific antigens, focusing on next-generation cancer immunotherapies. Utilizing its proprietary ImmunoPhage platform, Sensei Biotherapeutics creates immune-activating agents designed to engage both innate and adaptive immune systems. The company's TMAb (Tumor Microenvironment Activated Biologics) platform aims to develop selective therapeutics that either disable immunosuppressive signals or activate immunostimulatory signals within the tumor microenvironment. Sensei Biotherapeutics is advancing four investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which are in various stages of development. The company brings together expertise in biology, immunology, and oncology, supported by a seasoned management team and scientific advisors, to address unmet needs in cancer treatment.

Rejuveron Life Sciences AG, founded in 2019 and based in Zug, Switzerland, is a biotechnology platform company focused on developing and investing in therapies and technologies aimed at enhancing healthy aging and extending lifespan. The company seeks to advance innovative solutions by investing in promising ideas and talented individuals within the field of life sciences.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London, established in 2018. The company focuses on developing therapies for mental health disorders, utilizing psychedelic compounds and other innovative methods to address conditions such as depression, anxiety, and substance use disorders. ATAI collaborates with various partners and research institutions to advance its clinical-stage drug development pipeline, which includes multiple product candidates like psilocybin therapy, ketamine-based treatments, and other compounds aimed at enhancing mental well-being. The company's commitment to research in psychedelics and neuroscience drives its efforts to ensure the efficacy and safety of its therapies. Recognized for its contributions to mental health treatment, ATAI has secured partnerships and funding to support its initiatives, gaining attention for its advancements in understanding and treating mental health disorders.

Booster Therapeutics is a biotechnology company focused on developing innovative medicines aimed at addressing diseases associated with aging. The company specializes in regulating cellular homeostasis, a process essential for maintaining balance within cells. By targeting the cellular systems responsible for this regulation, Booster Therapeutics aims to eliminate toxic accumulations that can lead to various aging-related conditions. Through its research and development efforts, the company seeks to provide effective treatments that can prevent and manage these diseases, enhancing overall health and longevity.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London, established in 2018. The company focuses on developing therapies for mental health disorders, utilizing psychedelic compounds and other innovative methods to address conditions such as depression, anxiety, and substance use disorders. ATAI collaborates with various partners and research institutions to advance its clinical-stage drug development pipeline, which includes multiple product candidates like psilocybin therapy, ketamine-based treatments, and other compounds aimed at enhancing mental well-being. The company's commitment to research in psychedelics and neuroscience drives its efforts to ensure the efficacy and safety of its therapies. Recognized for its contributions to mental health treatment, ATAI has secured partnerships and funding to support its initiatives, gaining attention for its advancements in understanding and treating mental health disorders.